Evidence-Based Medicine and Rare Diseases

被引:11
作者
Day, Simon [1 ]
机构
[1] Roche Prod Ltd, Welwyn Garden City AL7 1TW, Herts, England
来源
RARE DISEASES EPIDEMIOLOGY | 2010年 / 686卷
关键词
Bias; Bradford Hill; Evidence; Meta-analysis; Patient preference; Precision; SMALL CLINICAL-TRIALS; 1ST PATIENT; THERAPIES; RANDOMIZE; APPROVAL; STROKE; RISKS; DRUGS; RATES; ISNT;
D O I
10.1007/978-90-481-9485-8_3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This chapter discusses the meaning of evidence-based medicine and where it relates to randomised controlled trials, but also where it does not. The need for good quality evidence is stressed through a discussion of high failure rates in drug development and arguments against access to unlicensed (and largely untested) treatments are set out (despite the good intentions of those who advocate such access to treatments). Good quality, reliable evidence does not always have to come from clinical trials. Other forms of evidence are discussed. Meta-analyses of individual trials may help to resolve the problem that, in rare diseases, it may be very difficult or impossible to do adequately powered clinical trials - but that does not imply those trials have no value at all. The importance of patients' choices is stressed but the difficulties of making choices and the general poor understanding of risk makes patients very vulnerable to making poor decisions. They need to be adequately guided through the evidence to make proper informed decisions.
引用
收藏
页码:41 / 53
页数:13
相关论文
共 30 条
[1]  
[Anonymous], 2000, Methods for meta-analysis in medical research
[2]  
[Anonymous], 2008, COCHRANE HDB SYSTEMA
[3]  
[Anonymous], 2002, Meta-Analysis of Controlled Clinical Trials
[4]  
Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
[5]   The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients [J].
Begg, Colin B. ;
Brawley, Otis ;
Califf, Robert M. ;
DeMets, David L. ;
Ellenberg, Susan S. ;
Kaplan, Richard S. ;
Rockhold, Frank W. .
CLINICAL TRIALS, 2006, 3 (02) :154-157
[6]   Oncology's trials [J].
Booth, B ;
Glassman, R ;
Ma, P .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (08) :609-610
[7]  
CHALMERS TC, 1977, NEW ENGL J MED, V296, P107
[8]   RANDOMIZATION OF 1ST PATIENT [J].
CHALMERS, TC .
MEDICAL CLINICS OF NORTH AMERICA, 1975, 59 (04) :1035-1038
[9]  
CHALMERS TC, 1968, LANCET, V1, P858
[10]  
Committee for Medicinal Products for Human Use (CHMP), 2006, GUID CLIN TRIALS SMA